Corticosterone up-regulates expression and function of norepinephrine transporter in SK-N-BE(2)C cells.
Glucocorticoids affect cellular and molecular events in brains by modulating the expression of many genes during stress. In the present study, we examined the regulatory effect of corticosterone on the expression and function of the norepinephrine transporter (NET) in vitro. The results show that exposure of SK-N-BE(2)C cells to corticosterone for 14 days significantly increased mRNA (up to 43%) and protein (up to 71%) levels of NET in the concentration-dependent manner. Longer exposure (21 days) resulted in greater increases in the levels of mRNAs (up to about 160%) and proteins (up to about 250%) of the NET. The up-regulatory effect of corticosterone on NET expression lasted a persistent period after cessation of exposure. Associated with the corticosterone-induced enhancement in NET expression, there was a parallel increase in the uptake of [(3)H]norepinephrine by SK-N-BE(2)C cells. Increased NET expression and function were abolished after exposure of cells to corticosterone in combination with mifepristone or spironolactone, two specific antagonists of corticosteroid receptors. This is consistent with the hypothesis that corticosterone-induced NET up-regulation is mediated by corticosteroid receptors. Nevertheless, there was no synergistic effect for a combination of both corticosteroid receptor antagonists. A similar up-regulation of NET protein levels was also observed after exposing PC12 cells to corticosterone. The present findings demonstrate that corticosterone up-regulates the expression and function of NET in vitro, indicating the action of corticosterone on the noradrenergic phenotype may play an important role in the correlation between stress and the development of depression.
Sun
Zhongwen
Z
Department of Pharmacology, Quillen College of Medicine, East Tennessee State University, Johnson City, TN 37604, USA.
Fan
Yan
Y
Zha
Qinqin
Q
Zhu
Meng-Yang
MY
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology*; D002461:Cell Line, Transformed; D045744:Cell Line, Tumor; D003345:Corticosterone / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D006727:Hormone Antagonists / Q000494:pharmacology; D006801:Humans; D015735:Mifepristone / Q000494:pharmacology; D009447:Neuroblastoma; D009638:Norepinephrine / Q000378:metabolism; D050484:Norepinephrine Plasma Membrane Transport Proteins / Q000235:genetics / Q000378:metabolism*; D012333:RNA, Messenger / Q000378:metabolism; D051381:Rats; D013148:Spironolactone / Q000494:pharmacology; D013997:Time Factors; D014316:Tritium / Q000378:metabolism; D015854:Up-Regulation / Q000187:drug effects*
D000893:Anti-Inflammatory Agents; D006727:Hormone Antagonists; D050484:Norepinephrine Plasma Membrane Transport Proteins; D012333:RNA, Messenger; D014316:Tritium; D013148:Spironolactone; D015735:Mifepristone; D003345:Corticosterone; D009638:Norepinephrine